Skin Cancer

FDA approves Novartis's advanced skin cancer drug



The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer.

The drug, Odomzo, will carry a boxed warning to alert the risks that it may cause death or severe birth defects in a developing fetus when administered to a pregnant woman. (